Project Details
Description
A Phase 2, Randomized Prospective, Double-Masked, Vehicle-Controlled Study to assess the Efficacy and Safety of Nexagon (NEXAGON) Applied Topically in Subjects with Corneal Persistent Epithelial Defects (PED) Resulting from Severe Ocular Chemical and/or
Status | Active |
---|---|
Effective start/end date | 7/15/19 → 7/31/24 |
Funding
- OCUNEXUS THERAPEUTICS, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.